Online citations, reference lists, and bibliographies.
← Back to Search

Polysaccharide Nanoparticles Can Efficiently Modulate The Immune Response Against An HIV Peptide Antigen

Tamara G. Dacoba, R. W. Omange, Hongzhao Li, J. Crecente-Campo, M. Luo, M. Alonso
Published 2019 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The development of an effective HIV vaccine continues to be a major health challenge since, so far, only the RV144 trial has demonstrated a modest clinical efficacy. Recently, the targeting of the 12 highly conserved protease cleavage sites (PCS1–12) has been presented as a strategy seeking to hamper the maturation and infectivity of HIV. To pursue this line of research, and because peptide antigens have low immunogenicity, we have included these peptides in engineered nanoparticles, aiming at overcoming this limitation. More specifically, we investigated whether the covalent attachment of a PCS peptide (PCS5) to polysaccharide-based nanoparticles, and their coadministration with polyinosinic:polycytidylic acid (poly(I:C)), improved the generated immune response. To this end, PCS5 was first conjugated to two different polysaccharides (chitosan and hyaluronic acid) through either a stable or a cleavable bond and then associated with an oppositely charged polymer (dextran sulfate and chitosan) and poly(I:C) to form the nanoparticles. Nanoparticles associating PCS5 by ionic interactions were used in this study as the control formulation. In vivo, all nanosystems elicited high anti-PCS5 antibodies. Nanoparticles containing PCS5 conjugated and poly(I:C) seemed to induce the strongest activation of antigen-presenting cells. Interestingly, T cell activation presented different kinetics depending on the prototype. These findings show that both the nanoparticle composition and the conjugation of the HIV peptide antigen may play an important role in the generation of humoral and cellular responses.
This paper references
10.1038/nature04790
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells
M. Williams (2006)
Memory T Cells and
F. Sallusto (2003)
10.1016/j.virol.2010.08.026
HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.
A. Caivano (2010)
10.1016/j.jconrel.2009.08.023
Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticles.
B. Sloat (2010)
10.1146/annurev.immunol.021908.132557
Blood monocytes: development, heterogeneity, and relationship with dendritic cells.
C. Auffray (2009)
10.1016/S1773-2247(06)50061-9
Chitosan nanocapsules: a new carrier for nasal peptide delivery
C. Prego (2006)
10.1146/ANNUREV.IMMUNOL.22.012703.104702
Central memory and effector memory T cell subsets: function, generation, and maintenance.
F. Sallusto (2004)
10.1073/pnas.1413550111
Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development
G. Lewis (2014)
10.1056/NEJMoa0908492
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
S. Rerks-Ngarm (2009)
10.1016/j.biomaterials.2016.10.047
Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Gaona Shi (2017)
Distinct Roles for the Costimulatory Ligands B 7 − 1 and B 7 − 2 in T Helper
C. B. Thompson
10.1126/SCIENCE.1071924
TNF-R1 Signaling: A Beautiful Pathway
G. Chen (2002)
10.1128/CVI.00425-10
Antibody Response to Polyhistidine-Tagged Peptide and Protein Antigens Attached to Liposomes via Lipid-Linked Nitrilotriacetic Acid in Mice
Douglas S. Watson (2010)
10.4049/jimmunol.165.4.1863
Oligosaccharides of Hyaluronan Are Potent Activators of Dendritic Cells1
C. Termeer (2000)
10.1021/nn403085w
Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation.
Nicholas M. Molino (2013)
10.1016/j.jconrel.2018.12.002
A multifunctional drug nanocarrier for efficient anticancer therapy.
Carmen Teijeiro-Valiño (2019)
10.1016/j.omtm.2018.10.010
Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA
N. Moyo (2019)
10.1021/acsami.6b01135
Hyaluronic Acid-Modified Cationic Lipid-PLGA Hybrid Nanoparticles as a Nanovaccine Induce Robust Humoral and Cellular Immune Responses.
Lanxia Liu (2016)
10.1128/JVI.67.7.4050-4055.1993
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.
A. Kaplan (1993)
10.1016/j.coi.2015.05.007
New approaches to HIV vaccine development.
B. Haynes (2015)
10.1016/S0092-8674(05)80001-7
Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation?
C. Thompson (1995)
10.1016/j.biotechadv.2015.05.010
Nanoengineering of vaccines using natural polysaccharides
A. S. Cordeiro (2015)
10.1016/j.jconrel.2016.11.012
Rational design of protamine nanocapsules as antigen delivery carriers
J. V. González-Aramundiz (2017)
10.1146/ANNUREV.IMMUNOL.25.022106.141548
Effector and memory CTL differentiation.
M. Williams (2007)
Intranasal Vaccination with Subunit Antigens
(2015)
10.1038/219305b0
Differentiation
J. Bonner (1968)
10.1016/j.addr.2013.05.013
Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
A. Hafner (2013)
10.1186/2050-7771-2-1
Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases
Jiyeon Yang (2013)
10.1146/annurev-med-052912-123749
Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
J. Kim (2015)
10.1186/s12981-017-0174-7
A novel HIV vaccine targeting the protease cleavage sites
Hongzhao Li (2017)
10.1016/j.ejpb.2015.09.019
Protamine-based nanoparticles as new antigen delivery systems.
J. V. González-Aramundiz (2015)
10.1371/journal.pone.0186079
Natural and cross-inducible anti-SIV antibodies in Mauritian cynomolgus macaques
Hongzhao Li (2017)
10.1126/scitranslmed.3006516
Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination
Adrienne V. Li (2013)
10.1016/S0264-410X(02)00407-3
Memory T cells and vaccines.
M. Esser (2003)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1021/acs.chemrev.5b00109
Synthetic Nanoparticles for Vaccines and Immunotherapy.
D. Irvine (2015)
10.1016/j.jconrel.2018.07.018
Bilayer polymeric nanocapsules: A formulation approach for a thermostable and adjuvanted E. coli antigen vaccine
J. Crecente-Campo (2018)
10.1128/CMR.9.4.532
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.
Daniel Lucey (1996)
10.1016/j.jconrel.2017.12.003
A strong adjuvant based on glycol‐chitosan‐coated lipid‐polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522
Fabrice Rose (2018)
10.1021/bc200148v
Tunable degradation of maleimide-thiol adducts in reducing environments.
Aaron D Baldwin (2011)
10.1016/j.addr.2016.02.010
Role of nanotechnology in HIV/AIDS vaccine development.
Y. Liu (2016)
10.1073/pnas.1100387108
Optimized clinical performance of growth hormone with an expanded genetic code
H. Cho (2011)
10.1016/j.vaccine.2014.03.041
Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization.
Q. Liu (2014)
10.1016/j.biomaterials.2009.01.026
Reduction-sensitive polymers and bioconjugates for biomedical applications.
F. Meng (2009)
10.1021/bc100596w
Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting.
Lina Cui (2011)
10.1039/c7bm00072c
Cyclopeptide scaffolds in carbohydrate-based synthetic vaccines.
Carlo Pifferi (2017)
10.1038/nrc.2016.108
Cancer nanomedicine: progress, challenges and opportunities
J. Shi (2017)
10.1016/j.jconrel.2017.05.014
Rational design of nanoparticles towards targeting antigen‐presenting cells and improved T cell priming
E. Zupančič (2017)
10.1016/j.smim.2017.09.007
Modulating the immune system through nanotechnology.
Tamara G. Dacoba (2017)
10.1016/j.jconrel.2015.04.010
Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens.
Yuchen Fan (2015)
10.1128/JVI.01844-16
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques
S. Kasturi (2016)
10.1021/nn405520d
Magnetic Field-Induced T Cell Receptor Clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor Activity
Karlo Perica (2014)
10.1016/J.JDDST.2015.08.010
Multi-enveloping of particulated antigens with biopolymers and immunostimulant polynucleotides
Jorge F. Correia-Pinto (2015)
Targeting Protease Cleavage Sites
H. Li (2013)
10.1021/JA00119A001
Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages
J. Shao (1995)
10.3389/fimmu.2012.00023
Regulation of Antigen-Experienced T Cells: Lessons from the Quintessential Memory Marker CD44
B. Baaten (2012)
10.1021/nn305466z
pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.
J. T. Wilson (2013)
10.1111/jmp.12300
Mauritian cynomolgus macaques with M3M4 MHC genotype control SIVmac251 infection
Hongzhao Li (2017)
10.1016/j.jconrel.2011.01.030
Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery.
R. Cheng (2011)
10.1021/acsnano.6b07343
Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery.
K. Gause (2017)
10.1016/j.cis.2018.11.008
Pharmaceutical applications of chitosan.
Z. Shariatinia (2019)
10.1002/jmv.24253
Conjugating influenza a (H1N1) antigen to n‐trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration
Q. Liu (2015)
10.1016/j.ijpharm.2010.09.003
Tresyl-based conjugation of protein antigen to lipid nanoparticles increases antigen immunogenicity.
Anekant Jain (2010)
Glutathione-Responsive NanoVehicles as a Promising Platform for Targeted Intracellular Drug and Gene Delivery
R. Cheng (2011)
10.3390/vaccines3030730
Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines
Jorge F. Correia-Pinto (2015)
10.1016/j.jconrel.2013.09.012
Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy.
Sara Vicente (2013)
10.1146/annurev.immunol.021908.132641
Regulation and function of NF-kappaB transcription factors in the immune system.
Sivakumar Vallabhapurapu (2009)
10.1146/ANNUREV.IMMUNOL.16.1.111
CD40 and CD154 in cell-mediated immunity.
I. Grewal (1998)
10.1016/j.jconrel.2012.03.017
Chitosan-based drug nanocarriers: where do we stand?
M. Garcia-Fuentes (2012)
10.3389/fimmu.2014.00491
Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
Guillermo Arango Duque (2014)
10.1073/pnas.1112648109
Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction
J. Moon (2012)
10.1002/jps.22763
Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles.
S. Sharma (2012)
10.1016/j.biomaterials.2014.04.010
Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen.
V. Temchura (2014)
10.1016/j.biomaterials.2018.01.004
Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma.
Huijuan Song (2018)
10.4049/jimmunol.1202958
Polyinosinic-Polycytidylic Acid Is the Most Effective TLR Adjuvant for SIV Gag Protein–Induced T Cell Responses In Nonhuman Primates
H. Park (2013)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1371/journal.pone.0062500
A Polymer/Oil Based Nanovaccine as a Single-Dose Immunization Approach
S. Vicente (2013)
10.1128/JVI.00443-17
Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses
Shridhar Bale (2017)
Distinct Roles for the Costimulatory Ligands B 7 - 1 and B 7 - 2 in T Helper
C. B. Thompson
10.1016/j.biomaterials.2017.04.020
Nanoencapsulation of individual mammalian cells with cytoprotective polymer shell.
J. Yang (2017)
10.1016/j.fct.2013.05.032
Immunostimulatory and antiangiogenic activities of low molecular weight hyaluronic acid.
Chunlin Ke (2013)
10.1016/j.vaccine.2013.04.057
Immunogenicity of sequences around HIV-1 protease cleavage sites: potential targets and population coverage analysis for a HIV vaccine targeting protease cleavage sites.
M. Luo (2013)
10.1126/SCIENCE.1142883
Monitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior
C. Auffray (2007)
10.1016/j.vaccine.2010.01.011
Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
C. Prego (2010)
10.1016/0167-5699(96)10060-I
The many roles of CD40 in cell-mediated inflammatory responses.
R. D. Stout (1996)
10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4
Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers
P. Calvo (1997)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar